AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges

Science Translational Medicine

Volumn 11, Issue 502, 2019, Pages

  Gardner, Matthew R ^a   Fellinger, Christoph H ^a   Kattenhorn, Lisa M ^b,f   Davis Gardner, Meredith E ^a   Weber, Jesse A ^a   Alfant, Barnett ^a   Zhou, Amber S ^a   Prasad, Neha R ^a   Kondur, Hema R ^a   Newton, Wendy A ^c   Weisgrau, Kimberly L ^c   Rakasz, Eva G ^c   Lifson, Jeffrey D ^d   Gao, Guangping ^e   Schultz Darken, Nancy ^c   Farzan, Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; CD4 ANTIGEN; ECD4 IG; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ISOLATION; VIRUS LOAD; ANIMAL; DEPENDOPARVOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; PATHOGENICITY; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HUMANS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE;

EID: 85069942264     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aau5409     Document Type: Article

References (53)

1. P. D. Kwong, J. R. Mascola, HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855-871 (2018).
2. R. Gautam, Y. Nishimura, N. Gaughan, A. Gazumyan, T. Schoofs, A. Buckler-White, M. S. Seaman, B. J. Swihart, D. A. Follmann, M. C. Nussenzweig, M. A. Martin, A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat. Med. 24, 610-616 (2018).
3. B. Julg, L. J. Tartaglia, B. F. Keele, K. Wagh, A. Pegu, D. Sok, P. Abbink, S. D. Schmidt, K. Wang, X. Chen, M. G. Joyce, I. S. Georgiev, M. Choe, P. D. Kwong, N. A. Doria-Rose, K. Le, M. K. Louder, R. T. Bailer, P. L. Moore, B. Korber, M. S. Seaman, S. S. Abdool Karim, L. Morris, R. A. Koup, J. R. Mascola, D. R. Burton, D. H. Barouch, Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, eaal1321 (2017).
4. B. Julg, A. Pegu, P. Abbink, J. Liu, A. Brinkman, K. Molloy, S. Mojta, A. Chandrashekar, K. Callow, K. Wang, X. Chen, S. D. Schmidt, J. Huang, R. A. Koup, M. S. Seaman, B. F. Keele, J. R. Mascola, M. Connors, D. H. Barouch, Virological control by the CD4-binding site antibody N6 in simian-human immunodeficiency virus-infected rhesus monkeys. J. Virol. 91, e00498-17 (2017).
5. B. Julg, P.-T. Liu, K. Wagh, W. M. Fischer, P. Abbink, N. B. Mercado, J. B. Whitney, J. P. Nkolola, K. McMahan, L. J. Tartaglia, E. N. Borducchi, S. Khatiwada, M. Kamath, J. A. LeSuer, M. S. Seaman, S. D. Schmidt, J. R. Mascola, D. R. Burton, B. T. Korber, D. H. Barouch, Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl. Med. 9, eaao4235 (2017).
6. J. Liu, K. Ghneim, D. Sok, W. J. Bosche, Y. Li, E. Chipriano, B. Berkemeier, K. Oswald, E. Borducchi, C. Cabral, L. Peter, A. Brinkman, M. Shetty, J. Jimenez, J. Mondesir, B. Lee, P. Giglio, A. Chandrashekar, P. Abbink, A. Colantonio, C. Gittens, C. Baker, W. Wagner, M. G. Lewis, W. Li, R.-P. Sekaly, J. D. Lifson, D. R. Burton, D. H. Barouch, Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353, 1045-1049 (2016).
7. R. Gautam, Y. Nishimura, A. Pegu, M. C. Nason, F. Klein, A. Gazumyan, J. Golijanin, A. Buckler-White, R. Sadjadpour, K. Wang, Z. Mankoff, S. D. Schmidt, J. D. Lifson, J. R. Mascola, M. C. Nussenzweig, M. A. Martin, A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105-109 (2016).
8. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak, J. D. Lifson, D. Dimitrov, M. C. Nussenzweig, M. A. Martin, Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
9. D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H.-W. Chang, K. Shekhar, S. Gupta, J. P. Nkolola, M. S. Seaman, K. M. Smith, E. N. Borducchi, C. Cabral, J. Y. Smith, S. Blackmore, S. Sanisetty, J. R. Perry, M. Beck, M. G. Lewis, W. Rinaldi, A. K. Chakraborty, P. Poignard, M. C. Nussenzweig, D. R. Burton, Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
10. M. R. Gaudinski, E. E. Coates, K. V. Houser, G. L. Chen, G. Yamshchikov, J. G. Saunders, L. A. Holman, I. Gordon, S. Plummer, C. S. Hendel, M. Conan-Cibotti, M. G. Lorenzo, S. Sitar, K. Carlton, C. Laurencot, R. T. Bailer, S. Narpala, A. B. McDermott, A. M. Namboodiri, J. P. Pandey, R. M. Schwartz, Z. Hu, R. A. Koup, E. Capparelli, B. S. Graham, J. R. Mascola, J. E. Ledgerwood; VRC 606 Study Team, Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A phase 1 open-label clinical trial in healthy adults. PLOS Med. 15, e1002493 (2018).
11. K. H. Mayer, K. E. Seaton, Y. Huang, N. Grunenberg, A. Isaacs, M. Allen, J. E. Ledgerwood, I. Frank, M. E. Sobieszczyk, L. R. Baden, B. Rodriguez, H. Van Tieu, G. D. Tomaras, A. Deal, D. Goodman, R. T. Bailer, G. Ferrari, R. Jensen, J. Hural, B. S. Graham, J. R. Mascola, L. Corey, D. C. Montefiori; HVTN 104 Protocol Team; NIAID HIV Vaccine Trials Network, Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLOS Med. 14, e1002435 (2017).
12. M. Caskey, T. Schoofs, H. Gruell, A. Settler, T. Karagounis, E. F. Kreider, B. Murrell, N. Pfeifer, L. Nogueira, T. Y. Oliveira, G. H. Learn, Y. Z. Cohen, C. Lehmann, D. Gillor, I. Shimeliovich, C. Unson-O'Brien, D. Weiland, A. Robles, T. Kummerle, C. Wyen, R. Levin, M. Witmer-Pack, K. Eren, C. Ignacio, S. Kiss, A. P. West Jr., H. Mouquet, B. S. Zingman, R. M. Gulick, T. Keler, P. J. Bjorkman, M. S. Seaman, B. H. Hahn, G. Fätkenheuer, S. J. Schlesinger, M. C. Nussenzweig, F. Klein, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185-191 (2017).
13. J. F. Scheid, J. A. Horwitz, Y. Bar-On, E. F. Kreider, C.-L. Lu, J. C. C. Lorenzi, A. Feldmann, M. Braunschweig, L. Nogueira, T. Oliveira, I. Shimeliovich, R. Patel, L. Burke, Y. Z. Cohen, S. Hadrigan, A. Settler, M. Witmer-Pack, A. P. West Jr., B. Juelg, T. Keler, T. Hawthorne, B. Zingman, R. M. Gulick, N. Pfeifer, G. H. Learn, M. S. Seaman, P. J. Bjorkman, F. Klein, S. J. Schlesinger, B. D. Walker, B. H. Hahn, M. C. Nussenzweig, M. Caskey, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556-560 (2016).
14. K. J. Bar, M. C. Sneller, L. J. Harrison, J. S. Justement, E. T. Overton, M. E. Petrone, D. B. Salantes, C. A. Seamon, B. Scheinfeld, R. W. Kwan, G. H. Learn, M. A. Proschan, E. F. Kreider, J. Blazkova, M. Bardsley, E. W. Refsland, M. Messer, K. E. Clarridge, N. B. Tustin, P. J. Madden, K. Oden, S. J. O'Dell, B. Jarocki, A. R. Shiakolas, R. L. Tressler, N. A. Doria-Rose, R. T. Bailer, J. E. Ledgerwood, E. V. Capparelli, R. M. Lynch, B. S. Graham, S. Moir, R. A. Koup, J. R. Mascola, J. A. Hoxie, A. S. Fauci, P. Tebas, T.-W. Chun, Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037-2050 (2016).
15. R. M. Lynch, E. Boritz, E. E. Coates, A. DeZure, P. Madden, P. Costner, M. E. Enama, S. Plummer, L. Holman, C. S. Hendel, I. Gordon, J. Casazza, M. Conan-Cibotti, S. A. Migueles, R. Tressler, R. T. Bailer, A. McDermott, S. Narpala, S. O'Dell, G. Wolf, J. D. Lifson, B. A. Freemire, R. J. Gorelick, J. P. Pandey, S. Mohan, N. Chomont, R. Fromentin, T.-W. Chun, A. S. Fauci, R. M. Schwartz, R. A. Koup, D. C. Douek, Z. Hu, E. Capparelli, B. S. Graham, J. R. Mascola, J. E. Ledgerwood; VRC 601 Study Team, Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
16. J. E. Ledgerwood, E. E. Coates, G. Yamshchikov, J. G. Saunders, L. Holman, M. E. Enama, A. DeZure, R. M. Lynch, I. Gordon, S. Plummer, C. S. Hendel, A. Pegu, M. Conan-Cibotti, S. Sitar, R. T. Bailer, S. Narpala, A. McDermott, M. Louder, S. O'Dell, S. Mohan, J. P. Pandey, R. M. Schwartz, Z. Hu, R. A. Koup, E. Capparelli, J. R. Mascola, B. S. Graham; VRC 602 Study Team, Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289-301 (2015).
17. M. Caskey, F. Klein, J. C. C. Lorenzi, M. S. Seaman, A. P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J. F. Scheid, J. A. Horwitz, I. Shimeliovich, S. Ben-Avraham, M. Witmer-Pack, M. Platten, C. Lehmann, L. A. Burke, T. Hawthorne, R. J. Gorelick, B. D. Walker, T. Keler, R. M. Gulick, G. Fatkenheuer, S. J. Schlesinger, M. C. Nussenzweig, Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
18. G. Buchlis, G. M. Podsakoff, A. Radu, S. M. Hawk, A. W. Flake, F. Mingozzi, K. A. High, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119, 3038-3041 (2012).
19. A. B. Balazs, Y. Ouyang, C. M. Hong, J. Chen, S. M. Nguyen, D. S. Rao, D. S. An, D. Baltimore, Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20, 296-300 (2014).
20. A. B. Balazs, J. Chen, C. M. Hong, D. S. Rao, L. Yang, D. Baltimore, Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84 (2012).
21. P. R. Johnson, B. C. Schnepp, J. Zhang, M. J. Connell, S. M. Greene, E. Yuste, R. C. Desrosiers, K. Reed Clark, Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901-906 (2009).
22. J. M. Martinez-Navio, S. P. Fuchs, S. Pedreño-López, E. G. Rakasz, G. Gao, R. C. Desrosiers, Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in rhesus monkeys. Mol. Ther. 24, 76-86 (2016).
23. K. O. Saunders, L. Wang, M. G. Joyce, Z.-Y. Yang, A. B. Balazs, C. Cheng, S.-Y. Ko, W.-P. Kong, R. S. Rudicell, I. S. Georgiev, L. Duan, K. E. Foulds, M. Donaldson, L. Xu, S. D. Schmidt, J.-P. Todd, D. Baltimore, M. Roederer, A. T. Haase, P. D. Kwong, S. S. Rao, J. R. Mascola, G. J. Nabel, Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J. Virol. 89, 8334-8345 (2015).
24. S. P. Fuchs, J. M. Martinez-Navio, M. Piatak Jr., J. D. Lifson, G. Gao, R. C. Desrosiers, AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLOS Pathog. 11, e1005090 (2015).
25. H. C. Welles, M. F. Jennewein, R. D. Mason, S. Narpala, L. Wang, C. Cheng, Y. Zhang, J.-P. Todd, J. D. Lifson, A. B. Balazs, G. Alter, A. B. McDermott, J. R. Mascola, M. Roederer, Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLOS Pathog. 14, e1007395 (2018).
26. I. Fetzer, M. R. Gardner, M. E. Davis-Gardner, N. R. Prasad, B. Alfant, J. A. Weber, M. Farzan, eCD4-Ig variants that more potently neutralize HIV-1. J. Virol. 92, e02011-17 (2018).
27. M. E. Davis-Gardner, M. R. Gardner, B. Alfant, M. Farzan, eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. PLOS Pathog. 13, e1006786 (2017).
28. M. R. Gardner, L. M. Kattenhorn, H. R. Kondur, M. von Schaewen, T. Dorfman, J. J. Chiang, K. G. Haworth, J. M. Decker, M. D. Alpert, C. C. Bailey, E. S. Neale, C. H. Fellinger, V. R. Joshi, S. P. Fuchs, J. M. Martinez-Navio, B. D. Quinlan, A. Y. Yao, H. Mouquet, J. Gorman, B. Zhang, P. Poignard, M. C. Nussenzweig, D. R. Burton, P. D. Kwong, M. Piatak, J. D. Lifson, G. Gao, R. C. Desrosiers, D. T. Evans, B. H. Hahn, A. Ploss, P. M. Cannon, M. S. Seaman, M. Farzan, AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87-91 (2015).
29. C. H. Fellinger, M. R. Gardner, C. C. Bailey, M. Farzan, Simian immunodeficiency virus SIVmac239, but not SIVmac316, binds and utilizes human CD4 more efficiently than rhesus CD4. J. Virol. 91, e00847-17 (2017).
30. D. Humes, S. Emery, E. Laws, J. Overbaugh, A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J. Virol. 86, 12472-12483 (2012).
31. M. R. Gardner, I. Fetzer, L. M. Kattenhorn, M. E. Davis-Gardner, A. S. Zhou, B. Alfant, J. A. Weber, H. R. Kondur, J. M. Martinez-Navio, S. P. Fuchs, R. C. Desrosiers, G. Gao, J. D. Lifson, M. Farzan, Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies. Mol. Ther. 27, 650-660 (2019).
32. J. H. Lee, R. Andrabi, C.-Y. Su, A. Yasmeen, J.-P. Julien, L. Kong, N. C. Wu, R. McBride, D. Sok, M. Pauthner, C. A. Cottrell, T. Nieusma, C. Blattner, J. C. Paulson, P. J. Klasse, I. A. Wilson, D. R. Burton, A. B. Ward, A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure. Immunity 46, 690-702 (2017).
33. D. Sok, M. J. van Gils, M. Pauthner, J.-P. Julien, K. L. Saye-Francisco, J. Hsueh, B. Briney, J. H. Lee, K. M. Le, P. S. Lee, Y. Hua, M. S. Seaman, J. P. Moore, A. B. Ward, I. A. Wilson, R. W. Sanders, D. R. Burton, Recombinant HIV envelope trimer selects for quaternarydependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. U.S.A. 111, 17624-17629 (2014).
34. E. White, F. Wu, E. Chertova, J. Bess, J. D. Roser, J. D. Lifson, V. M. Hirsch, Truncating the gp41 cytoplasmic tail of simian immunodeficiency virus decreases sensitivity to neutralizing antibodies without increasing the envelope content of virions. J. Virol. 92, e01688-17 (2018).
35. E. Yuste, W. Johnson, G. N. Pavlakis, R. C. Desrosiers, Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J. Virol. 79, 12455-12463 (2005).
36. C. H. Fellinger, M. R. Gardner, J. A. Weber, B. Alfant, A. S. Zhou, M. Farzan, eCD4-Ig limits HIV-1 escape more effectively than CD4-Ig or a broadly neutralizing antibody. J. Virol. 93, e00443-19 (2019).
37. A. N. Cline, J. W. Bess, M. Piatak Jr., J. D. Lifson, Highly sensitive SIV plasma viral load assay: Practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303-312 (2005).
38. E. J. Platt, M. Bilska, S. L. Kozak, D. Kabat, D. C. Montefiori, Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83, 8289-8292 (2009).
39. Y. Takeuchi, M. O. McClure, M. Pizzato, Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus Research. J. Virol. 82, 12585-12588 (2008).
40. X. Wei, J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, J. C. Kappes, Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905 (2002).
41. C. A. Derdeyn, J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, E. Hunter, Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74, 8358-8367 (2000).
42. E. J. Platt, K. Wehrly, S. E. Kuhmann, B. Chesebro, D. Kabat, Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855-2864 (1998).
43. M. R. Gardner, C. H. Fellinger, N. R. Prasad, A. S. Zhou, H. R. Kondur, V. R. Joshi, B. D. Quinlan, M. Farzan, CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. J. Virol. 90, 7822-7832 (2016).
44. M. D. Alpert, L. N. Heyer, D. E. J. Williams, J. D. Harvey, T. Greenough, M. Allhorn, D. T. Evans, A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 86, 12039-12052 (2012).
45. M. D. Alpert, J. D. Harvey, W. A. Lauer, R. K. Reeves, M. Piatak Jr., A. Carville, K. G. Mansfield, J. D. Lifson, W. Li, R. C. Desrosiers, R. P. Johnson, D. T. Evans, ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge. PLOS Pathog. 8, e1002890 (2012).
46. A. Trkola, J. Matthews, C. Gordon, T. Ketas, J. P. Moore, A Cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 73, 8966-8974 (1999).
47. H. K. Lyerly, D. L. Reed, T. J. Matthews, A. J. Langlois, P. A. Ahearne, S. R. Petteway Jr., K. J. Weinhold, Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retroviruses 3, 409-422 (1987).
48. D. N. Howell, P. E. Andreotti, J. R. Dawson, P. Cresswell, Natural killing target antigens as inducers of interferon: Studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J. Immunol. 134, 971-976 (1985).
49. D. A. Regier, R. C. Desrosiers, The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6, 1221-1231 (1990).
50. K. Honarmand Ebrahimi, G. M. West, R. Flefil, Mass spectrometry approach and ELISA reveal the effect of codon optimization on N-linked glycosylation of HIV-1 gp120. J. Proteome Res. 13, 5801-5811 (2014).
51. M. Li, F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, D. C. Montefiori, Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
52. C. Mueller, D. Ratner, L. Zhong, M. Esteves-Sena, G. Gao, Production and discovery of novel recombinant adeno-associated viral vectors. Curr. Protoc. Microbiol. 26, 14D.1.1-14D.1.21 (2012).
53. K. A. Buckley, P.-L. Li, A. H. Khimani, R. Hofmann-Lehmann, V. Liska, D. C. Anderson, H. M. McClure, R. M. Ruprecht, Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA. Virology 312, 470-480 (2003).